Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins : Targets of Human Amniotic Membrane in Hepatocellular Carcinoma
The anticancer effects of human amniotic membrane (hAM) have been studied over the last decade. However, the action mechanisms responsible for these effects are not fully understood until now. Previously results reported by our team proved that hAM is able to induce cytotoxicity and cell death in hepatocellular carcinoma (HCC), a worldwide high incident and mortal cancer. Therefore, this experimental study aimed to investigate the cellular targets of hAM protein extracts (hAMPE) in HCC through in vitro studies. Our results showed that hAMPE is able to modify oxidative stress environment in all HCC cell lines, as well as its cell cycle. hAMPE differently targets deoxyribonucleic acid (DNA), P21, P53, β-catenin and multidrug resistance (MDR) proteins in HCC cell lines. In conclusion, hAMPE has several targets in HCC, being clear that the success of this treatment depends of a personalized therapy based on the biological and genetic characteristics of the tumor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Pathology oncology research : POR - 22(2016), 4 vom: 15. Okt., Seite 689-97 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mamede, A C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.03.2017 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12253-016-0053-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM258309873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM258309873 | ||
| 003 | DE-627 | ||
| 005 | 20231224184731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12253-016-0053-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0861.xml |
| 035 | |a (DE-627)NLM258309873 | ||
| 035 | |a (NLM)26965246 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mamede, A C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins |b Targets of Human Amniotic Membrane in Hepatocellular Carcinoma |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The anticancer effects of human amniotic membrane (hAM) have been studied over the last decade. However, the action mechanisms responsible for these effects are not fully understood until now. Previously results reported by our team proved that hAM is able to induce cytotoxicity and cell death in hepatocellular carcinoma (HCC), a worldwide high incident and mortal cancer. Therefore, this experimental study aimed to investigate the cellular targets of hAM protein extracts (hAMPE) in HCC through in vitro studies. Our results showed that hAMPE is able to modify oxidative stress environment in all HCC cell lines, as well as its cell cycle. hAMPE differently targets deoxyribonucleic acid (DNA), P21, P53, β-catenin and multidrug resistance (MDR) proteins in HCC cell lines. In conclusion, hAMPE has several targets in HCC, being clear that the success of this treatment depends of a personalized therapy based on the biological and genetic characteristics of the tumor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell cycle | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Human amniotic membrane | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a Protein extracts | |
| 650 | 4 | |a hAMPE | |
| 650 | 7 | |a ATP Binding Cassette Transporter, Subfamily B |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a CDKN1A protein, human |2 NLM | |
| 650 | 7 | |a Cell Cycle Proteins |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p21 |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a beta Catenin |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 700 | 1 | |a Guerra, S |e verfasserin |4 aut | |
| 700 | 1 | |a Laranjo, M |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, K |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, M J |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalheiro, T |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, P |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, A |e verfasserin |4 aut | |
| 700 | 1 | |a Abrantes, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Maia, C J |e verfasserin |4 aut | |
| 700 | 1 | |a Botelho, M F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathology oncology research : POR |d 1995 |g 22(2016), 4 vom: 15. Okt., Seite 689-97 |w (DE-627)NLM094961379 |x 1532-2807 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2016 |g number:4 |g day:15 |g month:10 |g pages:689-97 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12253-016-0053-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2016 |e 4 |b 15 |c 10 |h 689-97 | ||